Accessibility Statement Skip Navigation
  • PRNewswire.com
  • Resources
  • +91 22-69790010
  • Client Login
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please use Advanced Search to search all press releases.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +91 22-69790010 from 9 AM - 5:30 PM IST

    • Contact
    • Contact

      +91 22-69790010
      from 9 AM - 5:30 PM IST

  • Request More Information
  • Journalists
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Request More Information
  • Journalists
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Request More Information
  • Journalists
  • General Inquiries
  • Worldwide Offices
  • Request More Information
  • Journalists

ESIC Medical College and Hospital, Faridabad announces Positive Results of a clinical study evaluating Nisarga Herbs' Neem Capsules for Prevention of COVID-19


News provided by

Nisarga Biotech Pvt Ltd.

27 Apr, 2021, 15:00 IST

Share this article

Share toX

Share this article

Share toX

- The study shows this Neem Formulation in a double-blind trial successfully indicated 55% efficacy in prevention of Covid-19

FARIDABAD, India, April 27, 2021 /PRNewswire/ -- ESIC Medical College and Hospital, Faridabad and Nisarga Biotech Pvt. Ltd today announced the final data from a pilot, double-blind, randomized, placebo-controlled trial studying prophylactic activity of a proprietary, patent-pending, Neem-leaf extract (Azadirachta Indica A. Juss) of Nisarga Biotech in healthcare personnel and relatives in daily contact with COVID-19 patients. The study was a planned collaboration of ESIC Medical College and Hospital, Faridabad & All India Institute of Ayurveda (AIIA), New Delhi, and was sponsored by Nisarga Biotech Pvt. Ltd, Satara, MS.

The study was conducted in 190 participants of aged 18-60 years at ESIC Medical College and Hospital, Faridabad, between August to December 2020 under the Principal Investigator Prof. (Dr.) Tanuja Nesari, MD, PhD, Director, AIIA & Co Investigator Dr. A. K Pandey ESIC Medical College & Hospital, Faridabad. The study was approved by the Institutional Ethics Committee and registered at Clinical Trial Registry of India (CTRI) and was conducted in accordance with Good Clinical Practice guidelines and according to all applicable local regulatory and ethical requirements.

Results demonstrated the probability of COVID-19 infection in participants receiving Neem capsules 50 mg twice a day for 28-days was reduced to less than half (a relative risk of 0.45) that of participants receiving the placebo, with the effectiveness of Neem capsules being around 55%. Biomarkers and Quality of life (QOL) remained stable in both groups.

Explaining the significance of the results, Dr. Anil Kumar Pandey, MD, Registrar, ESIC Medical College and Hospital, Faridabad, said, "Ayurveda has immense contribution in prophylaxis of various diseases. These study findings are a leap forward for prophylaxis against the COVID 19 specially when there is no specific treatment available for treatment of Covid-19 infection. I am sure it will work great as a preventive as well as additional protection even during the two doses of vaccination where chances of infection are there. Safety is another critical component for prophylactic measures, and we are encouraged to see that the Neem formulation studied in this study has a better and acceptable safety profile."

"Despite a number of SARS-CoV-2 vaccines gaining marketing authorization, COVID-19 continues to spread, and the majority of Indian population still need effective prophylactic treatment. We are extremely pleased with the outcome of this trial which provides early indications of the potential role of a proprietary, neem-leaf extract from Nisarga Biotech for the prophylaxis of COVID-19," said Dr. Asim Das, Dean, ESIC Medical College and Hospital.

Girish Soman, Founder and CEO of Nisarga Biotech Pvt. Ltd said, "Nisarga is the first manufacturer to conduct a double-blind placebo-controlled trial for prevention of Covid 19 with comparable efficacy to Vaccines. This is one of the first studies published in peer reviewed international journal in collaboration with two of India's renowned Ayurveda and medical institutes - AIIA and ESIC Medical College and Hospital, Faridabad. Our Neem formulation has proven to be an effective antiviral in preventive use against COVID-19 with a preventive efficacy rate of 55%. With the second wave hitting the country, our neem formulation is a great alternative for prevention of COVID-19 till the vaccines are widely and easily available in the country."

The study results have been published in PubMed indexed, peer reviewed journal "Alternative Therapies in Health and Medicine" one of the oldest professional medical journals that covers holistic, natural and alternative medical treatments, in USA and is available online at https://pubmed.ncbi.nlm.nih.gov/33891569/  More information on this clinical study can be found at Clinical Trial Registry of India (CTRI).http://ctri.nic.in. (CTRI/2020/07/026560)

About Nisarga Biotech and Nisarga Herbs:

Nisarga Biotech has a significant presence in India and USA and is marketing various herbal extracts for 20 years and supplements under brands Rebel Herbs and Intelligence Tree in USA for last 10 years. Nisarga Herbs is the herbal supplement brand manufactured and promoted in India with a slogan "Everyday a Healthy way" offering a wide range of health products backed by several national and international patents filed by them for various ailments. Nisarga Herbs products are available on www.nisargaherbs.com as well as on Amazon.

Modal title

Contact PR Newswire

  • +91 22-69790010

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+91 (0) 22 6169 6000
from 9 AM - 5:30 PM IST
  • Terms of Use
  • Privacy Policy
  • GDPR
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2025 Cision US Inc.